

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Bunschoten, <i>et al.</i>	Title:	METHOD OF CONTROLLED OVARIAN HYPERSTIMULATION AND PHARMACEUTICAL KIT FOR USE IN SUCH METHOD
App. No.:	10/517,028		
Conf. No.:	2857		
Filing Date:	June 15, 2005	Art Unit:	1654
		Examiner:	Harle, Jennifer I.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97 AND 1.98

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with 37 C.F.R. § 1.97 and the continuing duty of disclosure under 37 C.F.R. § 1.56, and §§ 1.97 - 1.987 as supplemented by MPEP § 609, Applicants call to the attention of the Examiner the references listed on the attached Form PTO/SB08A. It is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08A be considered by the Examiner and made of record. A list of all enclosed documents is provided in a Form PTO-1449, transmitted herewith. Presentation of documents listed on enclosed Form PTO-1449 is not an admission that any listed document is prior art under the Patent Statutes and the right is reserved to antedate any material described in the listed documents by a showing under 37 C.F.R. § 1.131 or otherwise.

This information disclosure statement is being filed after the period specified in 37 C.F.R. § 1.97(b) but prior to the date the prosecution of the application closes, in accordance with 37 C.F.R. § 1.97(c). Accordingly, Applicants respectfully request that the statement be considered by the Office in the course of prosecution of the application.

This Information Disclosure Statement does not include copies of cited U.S. patents and U.S. patent publications pursuant to 37 C.F.R. 1.98(a)(2).

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 CFR §1.97(g)), an admission that the information cited is or is considered to be material to patentability, or that no other material information exists.

A fee of \$180 is believed to be due in connection with the filing of this Information Disclosure Statement, in accordance with 37 CFR § 1.17(p). Should any other fees be deemed necessary for any reason relating to this document, the Commissioner is hereby authorized to deduct the fees from Howrey LLP Deposit Account 08-3038.

Respectfully submitted,

HOWREY LLP

Dated: April 10, 2008

By: /David W. Clough/Reg. No. 36,107

David W. Clough, Ph.D.

Registration No.: 36,107

Direct Dial No.: (312) 595-1408

Enclosures:

Form PTO-SB-08A

CUSTOMER NO.: 22930

HOWREY LLP

ATTN: Docketing Department

2941 Fairview Park Drive, Suite 200

Falls Church, VA 22042-9922

Telephone No.: (703) 663-3600

Facsimile No.: (703) 336-6950